Art. 2 Directive (EU) 1989/105

In forcesince 21 Dec 1988cited 14×

The following provisions shall apply if the marketing of a medicinal product is permitted only after the competent authorities of the Member State concerned have approved the price of the product:

1.

Member States shall ensure that a decision on the price which may be charged for the medicinal product concerned is adopted and communicated to the applicant within 90 days of the receipt of an application submitted, in accordance with the requirements laid down in the Member State concerned, by the holder of a marketing authorization. The applicant shall furnish the competent authorities with adequate information. If the information supporting the application is inadequate, the competent authorities shall forthwith notify the applicant of what detailed additional information is required and take their final decision within 90 days of receipt of this additional information. In the absence of such a decision within the abovementioned period or periods, the applicant shall be entitled to market the product at the price proposed.

2.

Should the competent authorities decide not to permit the marketing of the medicinal product concerned at the price proposed by the applicant, the decision shall contain a statement of reasons based on objective and verifiable criteria. In addition, the applicant shall be informed of the remedies available to him under the laws in force and the time limits allowed for applying for such remedies.

3.

At least once a year, the competent authorities shall publish in an appropriate publication, and communicate to the Commission, a list of the medicinal products the price of which has been fixed during the relevant period, together with the prices which may be charged for such products.

The 10 that are cited most themselves, of 14.

  • Judgment of the Court (Fifth Chamber) of 26 October 2006. G. Pohl-Boskamp GmbH & Co. KG v Gemeinsamer Bundesausschuss.Decision

    … qui exemptent des substances thérapeutiques de cette exclusion, sans prévoir une procédure conformément à l'article 6, points 1, deuxième phrase, et 2, de la directive 89/105? Convient-il d'interpréter la directive 89/105 […] en …

    26 Oct 2006 · 62005CJ0317

  • Judgment of the Court (Seventh Chamber) of 22 December 2022. Syndicat Les Entreprises du Médicament (LEEM) v Ministre des Solidarités et de Decision

    In that regard, Articles 2 and 3 of that directive, which concern, respectively, situations in which approval of the price of a medicinal product is required before it is marketed and situations in which an increase in the price of a …

    22 Dec 2022 · 62022CJ0020

  • Opinion of Mr Advocate General Ruiz-Jarabo Colomer delivered on 1 April 2008. Sot. Lélos kai Sia EE and Others v GlaxoSmithKline AEVE FarmakDecision

    1 Apr 2008 · 62006CC0468

  • BSG, Urteil vom 3. Mai 2018 - B 3 KR 7/17 RDecision

    3 May 2018 · KSRE147820218

  • Judgment of the Court (Third Chamber) of 26 February 2015. Les Laboratoires Servier SA v Ministre des Affaires sociales et de la Santé and MDecision

    Член 2, точки 1 и 2 от Директива 89/105 гласи: „Ако продажбата на даден лекарствен продукт е била разрешена едва след одобрение на …

    26 Feb 2015 · 62013CJ0691

  • Opinion of Mr Advocate General Jääskinen delivered on 11 February 2010. The Queen, on the application of Association of the British PharmaceDecision

    … f.eks. artikel 2, stk. 3, artikel 3, stk. 3, artikel 6, stk. 3 og 4, artikel 7, stk. 4, og artikel 8, stk. 1 og 2, i direktiv 89/105.].

    11 Feb 2010 · 62009CC0062

  • Opinion of Advocate General Trstenjak delivered on 13 November 2008. A. Menarini Industrie Farmaceutiche Riunite Srl and Others v Ministero Decision

    … see Pohl-Boskamp , cited in footnote 50, paragraph 29. (63) – Under the Directive, in some cases, for example under Article 2(1) of Directive 89/105, the application will be granted automatically if the authority fails to adhere to the …

    13 Nov 2008 · 62007CC0352

  • Opinion of Mr Advocate General Tizzano delivered on 11 July 2002. Commission of the European Communities v République de Finlande.Decision

    Article 2 of the Directive provides that: ‘The following provisions shall apply if the marketing of a medicinal product is permitted only after the competent authorities of the Member State concerned have approved the price of the …

    11 Jul 2002 · 62000CC0229

  • Conseil d'État, 1ère chambre jugeant seule, 27 juin 2024, n° 449049, inédit au recueil LebonDecision

    … de l'article 34 du traité sur le fonctionnement de l'Union européenne, du principe de non-discrimination et des articles 1, 2, 3 et 11 de la directive 89/105/CEE du Conseil, du 21 décembre 1988, concernant la transparence des mesures …

    27 Jun 2024 · DCE_449049_20240627

  • Conseil d'État, 1ère chambre, 27/06/2024, 449049, Inédit au recueil LebonDecision

    27 Jun 2024 · CETATEXT000049823551